PRN: Frontier Pharma Report: Breast Cancer Market 2016 - Treatment Pipeline?s Exceptional Levels of Activity and Innovation May Significantly Alter the Clinical and Commercial Landscape Over the Next Decade

PRN: Frontier Pharma Report: Breast Cancer Market 2016 - Treatment Pipeline?s Exceptional Levels of Activity and Innovation May Significantly Alter the Clinical and Commercial Landscape Over the Next Decade.

Persone Laura Wood, May Significantly Alter
Luoghi Dublino, Stati Uniti d'America
Organizzazioni Hours
Argomenti internet, marketing, commercio, economia

24/mar/2016 11:12:00 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Frontier Pharma Report: Breast Cancer Market 2016 - Treatment Pipeline?s Exceptional Levels of Activity and Innovation May Significantly Alter the Clinical and Commercial Landscape Over the Next Decade

 
[24-March-2016]
 

DUBLIN, March 24, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/mgwl93/frontier_pharma) has announced the addition of the "Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes" report to their offering.

The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. The degree and proportion of breakthrough innovations in this pipeline is exceptional.

This analysis identified 333 first-in-class programs in the breast cancer pipeline, acting on 251 first-in-class molecular targets. This accounts for some 39% of all products with a disclosed molecular target, and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as despite the high attrition rate in breast cancer, it is highly likely many of the first-in-class products will reach the market over the coming decade and, will have the opportunity to transform the clinical and commercial landscape.

Potential driving factors behind this market include a very large and growing patient pool, a well-established disease market with a number of strong unmet needs, and the strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fill the unmet needs.

Some 289 first-in-class products that are currently in development have not yet been involved in licensing or co-development deals, meaning there are numerous opportunities for in-licensing or co-development in this indication, which already has a strong track record of breakthrough innovation yielding highly commercially and clinically successful therapies.

Key Topics Covered:

1  Tables & Figures

2 Executive Summary

2.1 Exceptionally Large and Innovative Pipeline

2.2 Alignment of First-in-Class Molecular Target with Disease Causation

2.3 Highly Active Deals Landscape with Numerous Investment Opportunities

3 The Case for Innovation in the Breast Cancer Market

3.1 Growing Opportunities for Biologic Products

3.2 Diversification of Molecular Targets

3.3 Innovative First-in-Class Product Developments Remain Attractive

3.4 Changes in Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications

3.5 Sustained Innovation

3.6 Report Guidance

4 Clinical and Commercial Landscape

4.1 Disease Overview

4.2 Epidemiology

4.3 Disease Symptoms

4.4 Etiology

4.5 Pathophysiology

4.6 Diagnosis

4.7 Prognosis and Disease Staging

4.8 Introduction to Breast Cancer Treatments

4.9 Surgery and Radiation Therapy

4.10 Overview of Marketed Products for Breast Cancer

4.11 Treatment Algorithm

4.12 Current Unmet Need in Breast Cancer Market

5 Assessment of Pipeline Product Innovation

5.1 Breast Cancer Pipeline by Phase, Molecule Type and Molecular Target

5.2 First-in-Class Pipeline Programs

6 Signaling Network, Disease Causation and Innovation Alignment

6.1 The Complexity of Signaling Networks in Oncology

6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration

6.3 First-in-Class Target Matrix Assessment

7 First-in-Class Target Evaluation

7.1 Pipeline Programs which Target FGFR 3 and 4

7.2 Pipeline Programs which Target HER3

7.3 Pipeline Programs which Target PDK1

7.4 Pipeline Programs which Target Akt 1, 2 and 3

7.5 Pipeline Programs which Target PI3K-alpha

7.6 Conclusion

8 Deals and Strategic Consolidations

8.1 Industry-Wide First-in-Class Deals

8.2 Breast Cancer Deals Landscape

8.3 Licensing Deals

8.3.1 Molecule Type

8.3.2 Molecular Target

8.4 Co-development Deals

8.5 First-In-Class Molecules not Involved in Licensing or Co-development Deals

9 Appendix

For more information visit http://www.researchandmarkets.com/research/mgwl93/frontier_pharma

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl